[go: up one dir, main page]

CL2016002089A1 - Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen - Google Patents

Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen

Info

Publication number
CL2016002089A1
CL2016002089A1 CL2016002089A CL2016002089A CL2016002089A1 CL 2016002089 A1 CL2016002089 A1 CL 2016002089A1 CL 2016002089 A CL2016002089 A CL 2016002089A CL 2016002089 A CL2016002089 A CL 2016002089A CL 2016002089 A1 CL2016002089 A1 CL 2016002089A1
Authority
CL
Chile
Prior art keywords
pharmaceutical compositions
preparation procedure
compositions containing
isoquinoline derivatives
isoquinoline
Prior art date
Application number
CL2016002089A
Other languages
English (en)
Inventor
Stefano Chimenti
Christine Courchay
AIMéE DESSINGES
Françoise Gellibert
Bertrand Goument
Marc Konnert
Jean-Louis Peglion
Christophe Poitevin
Jean-Paul Vilaine
Nicole Villeneuve
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of CL2016002089A1 publication Critical patent/CL2016002089A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

<p>COMPUESTOS DERIVADOS DE ISOQUINOLEÍNA; SU PROCEDIMIENTO DE PREPARACIÓN; COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN;  Y SU USO PARA EL TRATAMIENTO DE LA HIPERTENSION ARTERIAL, ANGINA, INFARTO DE MIOCARDIO, GLAUCOMA, ENTRE OTROS.</p>
CL2016002089A 2014-02-21 2016-08-18 Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen CL2016002089A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1451389A FR3017868A1 (fr) 2014-02-21 2014-02-21 Derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
CL2016002089A1 true CL2016002089A1 (es) 2017-01-27

Family

ID=50424640

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016002089A CL2016002089A1 (es) 2014-02-21 2016-08-18 Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen

Country Status (37)

Country Link
US (1) US9809553B2 (es)
EP (1) EP3107900B1 (es)
JP (1) JP6491226B2 (es)
KR (1) KR102251198B1 (es)
CN (1) CN105980361B (es)
AR (1) AR099493A1 (es)
AU (1) AU2015220659B2 (es)
BR (1) BR112016017679B1 (es)
CA (1) CA2938344C (es)
CL (1) CL2016002089A1 (es)
CY (1) CY1120034T1 (es)
DK (1) DK3107900T3 (es)
EA (1) EA030617B1 (es)
ES (1) ES2659885T3 (es)
FR (1) FR3017868A1 (es)
HR (1) HRP20180141T1 (es)
HU (1) HUE038337T2 (es)
IL (1) IL246721B (es)
JO (1) JO3372B1 (es)
LT (1) LT3107900T (es)
MA (1) MA39207A1 (es)
ME (1) ME02863B (es)
MX (1) MX363301B (es)
MY (1) MY178745A (es)
NO (1) NO3107900T3 (es)
NZ (1) NZ722513A (es)
PL (1) PL3107900T3 (es)
PT (1) PT3107900T (es)
RS (1) RS56766B1 (es)
RU (1) RU2679621C2 (es)
SG (1) SG11201605662TA (es)
SI (1) SI3107900T1 (es)
TW (1) TWI547484B (es)
UA (1) UA117953C2 (es)
UY (1) UY35997A (es)
WO (1) WO2015124877A1 (es)
ZA (1) ZA201604976B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3473621T (pt) * 2016-06-17 2021-10-04 Green Cross Corp Método de produção de derivados de difenilmetano
EP3801500B1 (en) 2018-06-07 2025-03-05 Disarm Therapeutics, Inc. Inhibitors of sarm1
WO2020007807A1 (en) * 2018-07-02 2020-01-09 Ecole Polytechnique Federale De Lausanne (Epfl) Lactate enhancing compounds and uses thereof
US10745381B2 (en) * 2018-11-06 2020-08-18 Cervello Therapeutics, Llc. Substituted isoquinolines and phthalazines as rock kinase inhibitors
US11248004B2 (en) 2018-11-06 2022-02-15 Cervello Therapeutics, Llc. Substituted isoquinolines as rock kinase inhibitors
KR102906316B1 (ko) 2019-03-01 2025-12-31 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 지방간 질환 및/또는 지방간염의 치료 방법
MX2021011364A (es) 2019-03-22 2021-10-13 Saniona As Inhibidores del canal de potasio novedosos.
JP7758664B2 (ja) 2019-10-30 2025-10-22 バイオジェン・エムエイ・インコーポレイテッド ブルトン型チロシンキナーゼに対する阻害剤としての縮合型二複素環
CN115974647B (zh) * 2022-12-05 2024-09-03 江苏宏邦化工科技有限公司 以四氢-4-甲基-2-苯基-2h-吡喃-4-醇为原料制备苯乐戊醇的方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3583287D1 (de) 1984-12-27 1991-07-25 Asahi Chemical Ind Substituierte isochinolinsulfonyl-verbindungen.
JPH07277979A (ja) * 1994-04-12 1995-10-24 Asahi Chem Ind Co Ltd 過粘性症候群治療または予防剤
WO2000064478A1 (en) 1999-04-27 2000-11-02 Mitsubishi Pharma Corporation Preventives/remedies for liver diseases
AU8824201A (en) * 2000-08-11 2002-02-25 Bristol Myers Squibb Co Process for the preparation of dinapsoline
EP1423381B1 (en) * 2001-09-06 2007-01-03 Schering Corporation 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
US6924290B2 (en) * 2002-01-23 2005-08-02 Bayer Pharmaceuticals Corporation Rho-kinase inhibitors
JP2007008816A (ja) 2003-10-15 2007-01-18 Ube Ind Ltd 新規イソキノリン誘導体
SI1899322T1 (sl) * 2005-06-28 2010-01-29 Sanofi Aventis Izokinolinski derivati kot inhibitorji Rho-kinaze
PT1910333E (pt) 2005-07-26 2013-08-01 Sanofi Sa Derivados de isoquinolona substituída com piperidinilo como inibidores da rho-cinase
CA2615663C (en) 2005-07-26 2013-10-15 Sanofi-Aventis Cyclohexylamin isoquinolone derivatives as rho-kinase inhibitors
US7867999B1 (en) * 2005-12-22 2011-01-11 Alcon Research, Ltd. Hydroxyamino- and amino-substituted pyridine analogs for treating rho kinase-mediated diseases and conditions
US7893088B2 (en) * 2006-08-18 2011-02-22 N.V. Organon 6-substituted isoquinoline derivatives
KR20090094338A (ko) 2006-12-27 2009-09-04 사노피-아벤티스 치환된 이소퀴놀린 및 이소퀴놀리논 유도체
RU2009128688A (ru) 2006-12-27 2011-02-10 Санофи-Авентис (Fr) Замещенные циклоалкиламином производные изохинолина и изохинолинона
CA2673916C (en) 2006-12-27 2015-02-17 Sanofi-Aventis Substituted isoquinolone and isoquinolinone derivatives as inhibitors of rho-kinase
WO2008077554A1 (en) 2006-12-27 2008-07-03 Sanofi-Aventis Cycloalkylamine substituted isoquinoline derivatives
WO2008077555A2 (en) * 2006-12-27 2008-07-03 Sanofi-Aventis Substituted isoquinolines and their use as rho-kinase inhibitors
BRPI0720859A2 (pt) 2006-12-27 2014-03-25 Sanofi Aventis Derivados de isoquinolina e isoquinolinona substituídos com cicloalquilamina
TW200845988A (en) * 2007-04-05 2008-12-01 Astrazeneca Ab New compounds and their uses 707
KR101607090B1 (ko) 2008-06-24 2016-03-29 사노피 6-치환된 이소퀴놀린 및 이소퀴놀리논
ES2541827T3 (es) 2008-06-24 2015-07-27 Sanofi Isoquinolinas e isoquinolinonas sustituidas como inhibidores de Rho-cinasa
NZ590067A (en) 2008-06-24 2012-09-28 Sanofi Aventis Bi-and polycyclic substituted isoquinoline and isoquinolinone derivatives as rho kinase inhibitors

Also Published As

Publication number Publication date
PT3107900T (pt) 2018-01-08
CN105980361B (zh) 2019-05-21
AU2015220659B2 (en) 2018-09-13
EA030617B1 (ru) 2018-08-31
BR112016017679A2 (es) 2017-08-08
US9809553B2 (en) 2017-11-07
AU2015220659A1 (en) 2016-08-04
CY1120034T1 (el) 2018-12-12
JP2017506251A (ja) 2017-03-02
LT3107900T (lt) 2017-12-27
FR3017868A1 (fr) 2015-08-28
UY35997A (es) 2015-08-31
KR102251198B1 (ko) 2021-05-11
CA2938344A1 (fr) 2015-08-27
SG11201605662TA (en) 2016-08-30
CN105980361A (zh) 2016-09-28
HUE038337T2 (hu) 2018-10-29
JO3372B1 (ar) 2019-03-13
ES2659885T3 (es) 2018-03-19
IL246721B (en) 2018-12-31
NZ722513A (en) 2019-08-30
MY178745A (en) 2020-10-20
HRP20180141T1 (hr) 2018-03-09
PL3107900T3 (pl) 2018-04-30
TW201534587A (zh) 2015-09-16
JP6491226B2 (ja) 2019-03-27
RU2016137502A3 (es) 2018-09-24
RS56766B1 (sr) 2018-04-30
RU2679621C2 (ru) 2019-02-12
MA39207A1 (fr) 2017-04-28
SI3107900T1 (en) 2018-02-28
ME02863B (me) 2018-04-20
MX363301B (es) 2019-03-20
US20170137385A1 (en) 2017-05-18
DK3107900T3 (en) 2018-02-19
UA117953C2 (uk) 2018-10-25
ZA201604976B (en) 2022-05-25
KR20160116003A (ko) 2016-10-06
EA201691675A1 (ru) 2017-02-28
HK1232220A1 (zh) 2018-01-05
WO2015124877A1 (fr) 2015-08-27
RU2016137502A (ru) 2018-03-27
BR112016017679B1 (pt) 2022-07-26
NO3107900T3 (es) 2018-04-14
EP3107900A1 (fr) 2016-12-28
AR099493A1 (es) 2016-07-27
TWI547484B (zh) 2016-09-01
CA2938344C (fr) 2018-07-03
EP3107900B1 (fr) 2017-11-15
MX2016010779A (es) 2016-10-26

Similar Documents

Publication Publication Date Title
SV2018005794A (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
CL2016002089A1 (es) Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
GT201700189A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
ECSP19003773A (es) Compuestos heterocíclicos como inmunomoduladores
CL2018000542A1 (es) Nuevos derivados de fenoximetilo.
CL2017000902A1 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CL2016002148A1 (es) Derivados de fenilen-1,5-diamina 2,4-disustituidos y aplicaciones de los mismos, y composiciones farmacéuticas y composiciones farmacéuticamente aceptables preparadas a partir de los mismos.
CL2017001923A1 (es) Derivados de 9h-pirrolo-dipiridina
CL2016001973A1 (es) Derivados de nucleosido sustituidos con 4&#39; -difluorometilo como inhibidores de la replicación de arn de la influenza.
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
UY37646A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CL2018001837A1 (es) Compuestos antiproliferativos y sus composiciones farmacéuticas y usos
ECSP16074478A (es) Compuestos novedosos
MX2017013875A (es) Ciertos inhibidores de la proteína quinasa.
UY35653A (es) Nuevos derivados de indol y de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CL2017000640A1 (es) Nuevos activadores de la guanilato ciclasa soluble y su uso
MX2018002416A (es) Derivados de 1,7-diaril-1,6-heptadien-3,5-diona, procedimiento para la preparación y uso de los mismos.
MX2017000183A (es) Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides.
GT201500143A (es) Composiciones que comprenden vortioxetina y donepezilo campo tecnico
UY36117A (es) Composiciones farmacéuticas para el tratamiento de enfermedades infecciosas.
DOP2018000066A (es) Compuestos útiles para inhibir ror-gamma-t
CL2019001804A1 (es) Activador de nrf2.
MX2017003589A (es) Compuestos de indolinona y usos de los mismos.
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
CL2017000663A1 (es) Uso de compuestos heterocíclicos fluoroalquenil sulfano para repeler moluscos